← Back to Search

Priming Intervention for Psoriasis

N/A
Waitlist Available
Led By Steven R Feldman
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Either diagnosed with psoriasis (ICD-9: 696.1) or a parent/caregiver of an individual diagnosed with psoriasis (ICD-9: 696.1).
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is testing how well patients do when given a choice of 3 different psoriasis treatments.

Who is the study for?
This trial is for English-speaking individuals with psoriasis or their caregivers. It's not open to those who have already tried and did not respond well to specific biologic drugs like ustekinumab, guselkumab, risankizumab, or tildrakizumab.Check my eligibility
What is being tested?
The study aims to understand how people with psoriasis feel about injectable biologic medications as a treatment option. Participants will be divided into groups receiving different educational interventions regarding these treatments.See study design
What are the potential side effects?
Since the focus of this trial is on patient perceptions rather than medication effects, it does not directly involve drug side effects. However, discussions may cover potential side effects of biologics used in psoriasis management.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have psoriasis or I am caring for someone with psoriasis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Oral Survey Responses

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Group #3 (Intervention)Experimental Treatment1 Intervention
Group #3 (Intervention) Survey 3 will be administered, and patients will be asked the following primer: Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis. What do you think would be the best way to describe this to a patient? Stelara® acts in an almost all-natural way to help control psoriasis. Stelara® blocks one of the genetic causes of psoriasis. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)
Group II: Group #2 (Intervention)Experimental Treatment1 Intervention
Group #2 (Intervention) Survey 2 will be administered, and patients will be asked the following primer: Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis. How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)
Group III: Group #1 (Control)Active Control1 Intervention
Group #1 (Control) Oral survey 1 will be administered and patients will be asked: Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,240 Previous Clinical Trials
1,004,027 Total Patients Enrolled
12 Trials studying Psoriasis
823 Patients Enrolled for Psoriasis
Steven R FeldmanPrincipal InvestigatorWake Forest University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis
2018. "A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03465696.
All > Psoriasis > Plaque Psoriasis
~26 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top